US Pharma MarketingHims & Hers announced it will offer generic semaglutide through its direct-to-consumer virtual care platform to eligible customers in Canada, following Novo Nordisk's loss of Canadian patent protection for Ozempic and Wegovy last year.
Hims & Hers launches generic semaglutide offering in Canada
Last year, Novo Nordisk lost its patent protection in Canada on its semaglutide-based drugs, Ozempic and Wegovy, after failing to pay a small maintenance fee to maintain it. Hims & Hers announced it will offer generic semaglutide through its direct-to-consumer virtual care platform to eligible customers in Canada, following Novo Nordisk's loss of Canadian patent protection for Ozempic and Wegovy last year. The San Francisco-based company offers a direct-to-consumer telehealth and wellness platform for weight loss and GLP-1 treatments, mental health care, sexual health, hair loss, dermatology, hormone support, primary care, lab testing and women’s health services, such as menopause…
Source: MobiHealthNews